BMO Capital Starts D-Wave Quantum at Outperform With $35 Target — 86% Upside From Latest Close
BMO cites real commercial revenue, a first-mover advantage, and a unique dual annealing-gate technology strategy.
NOTRELOAD AI
Alvotech Partners with Lotus on Biosimilars to Imfinzi and Hemlibra in the US and Asia
Alvotech partners with Lotus for biosimilars to Imfinzi and Hemlibra in the US and Asia. Deal worth up to $150M plus ongoing supply revenue.
Buyout Chatter Lifts TG Therapeutics Shares — But No Deal Confirmed
Unconfirmed buyout speculation tied to Betaville surrounds TG Therapeutics, maker of BRIUMVI for multiple sclerosis. No official deal talks disclosed.
Arbutus Biopharma Plans $230 Million Share Buyback After Moderna Patent Win
Arbutus Biopharma will repurchase up to $230M in shares via Dutch auction, funded by its $950M Moderna LNP patent settlement. Offer range $5–$5.75.
Nvidia’s $6 Billion ‘Non-Acquisition’ of Poolside: License, Talent, and a $12B Stake
Nvidia pays Poolside $6B for a non-exclusive license to its Model Factory, offers jobs to 109 staff, and invests $1B. Third such deal — not an acquisition.
Werewolf and Ambros Merge in $150M Deal to Advance First Potential FDA-Approved Treatment for CRPS-1
Werewolf and Ambros merge in all-stock deal with oversubscribed $150M funding to advance neridronate as potential first FDA-approved CRPS-1 treatment.